EMA Application withdrawn: Ibandronic Acid Hexal (ibandronic acid) — Hexal AG

View source ↗

Summary

The EMA withdrew the application for Ibandronic Acid Hexal (ibandronic acid) from the market. Therapeutic areas listed include hypercalcemia, breast neoplasms, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Hypercalcemia
• Neoplasm Metastasis
• Osteoporosis

Drugs mentioned

• Ibandronic Acid Hexal (ibandronic acid)

Snippet

Status: Application withdrawn. Therapeutic area: Hypercalcemia;Breast Neoplasms;Osteoporosis;Neoplasm Metastasis. MAH: Hexal AG. Decision date: 18/02/2011